Construction of A Prediction Model for Atrial Fibrillation in Patients with Dilated Cardiomyopathy and Heart Failure

Kaizheng Liu¹, Chengjie Liu²*

¹Department of Cardiac Surgery, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, China
²Foshan Fosun Chancheng Hospital, Foshan 528000, Guangdong Province, China

*Corresponding author: Chengjie Liu, lkzheng1996@163.com

Abstract: Dilated cardiomyopathy (DCM) is a common myocardial disease characterized by enlargement of the heart cavity and decreased systolic function, often leading to heart failure (HF) and arrhythmia. The occurrence of atrial fibrillation (AF) is closely related to the progression and prognosis of the disease. In recent years, with the advancement of medical imaging and biomarkers, models for predicting the occurrence of AF in DCM patients have gradually become a research hotspot. This article aims to review the current situation of AF in DCM patients and explore the importance and possible methods of constructing predictive models to provide reference for clinical prevention and treatment. We comprehensively analyzed the risk factors for AF in DCM patients from epidemiological data, pathophysiological mechanisms, clinical and laboratory indicators, electrocardiogram and imaging parameters, and biomarkers, and evaluated the effectiveness of existing predictive models. Through analysis of existing literature and research, this article proposes a predictive model that integrates multiple parameters to improve the accuracy of predicting AF in DCM patients and provide a scientific basis for personalized treatment.

Keywords: Dilated cardiomyopathy; Heart failure; Atrial fibrillation; Prediction model

Online publication: January 31, 2024

1. Introduction

Dilated cardiomyopathy (DCM) is a disease that primarily affects the myocardium, characterized by enlargement of the heart cavity and decreased myocardial contractility, and is one of the main causes of heart failure (HF) [1]. As the disease develops, the risk of atrial fibrillation (AF) in DCM patients significantly increases, which not only exacerbates the symptoms of HF but may also lead to severe complications such as thrombosis and stroke. Therefore, early identification of the risk of AF in DCM patients is of great significance for improving prognosis and guiding treatment [2].

In recent years, with the progress of medical technology, various methods including electrocardiogram,
cardiac magnetic resonance (CMR), and biomarker detection have been used to evaluate the condition and prognosis of DCM patients. However, it is still a challenge to integrate these parameters and construct an accurate model for predicting the occurrence of AF in DCM patients.

This article begins with a review of the epidemiological status of AF in DCM patients, followed by an exploration of its pathophysiological mechanisms and an analysis of the possibility and methods of constructing predictive models. Through the evaluation of existing research, this article aims to propose a comprehensive model to provide more accurate predictive tools for clinical practice, thereby achieving early identification and intervention of atrial fibrillation in DCM patients.

2. Epidemiology of dilated cardiomyopathy and atrial fibrillation

2.1. Epidemiological data of dilated cardiomyopathy

DCM is one of the most common cardiomyopathies worldwide, characterized by enlargement of the heart cavity and weakened systolic function. It is estimated that the incidence rate of DCM is about 36 new cases per 100,000 people, but this number varies in different regions and populations. DCM can be hereditary or acquired, which may be related to factors such as viral infection, alcohol abuse, toxin exposure, and malnutrition. Despite extensive treatment methods, the 5-year survival rate of DCM patients remains below 50%.

2.2. Incidence rate of AF in patients with HF

AF is the most common arrhythmia in patients with HF, and its incidence rate increases with the severity of HF. In DCM patients, the incidence of AF can be as high as 25% to 50%, which increases with disease progression and patient age. The occurrence of AF not only exacerbates the symptoms of HF but is also associated with an increased risk of cardiovascular events.

2.3. Effect of AF on the prognosis of DCM

The occurrence of atrial fibrillation in DCM patients is a poor prognostic factor, closely related to higher mortality and cardiovascular complications. AF can lead to a decrease in cardiac output, exacerbate HF symptoms, and increase the risk of thrombosis, leading to stroke and other vascular events. In addition, AF may also lead to further deterioration of cardiac structure and function, forming a vicious cycle. Therefore, early identification and management of AF in DCM patients is crucial for improving prognosis.

3. Pathophysiological mechanism of AF

3.1. Myocardial fibrosis and atrial structural remodeling

Myocardial fibrosis is a key pathophysiological basis for the occurrence of AF. In the context of DCM, the death and damage of myocardial cells lead to the deposition of collagen fibers, leading to structural remodeling of the myocardium. This structural change not only increases the rigidity of the atrial tissue but also disrupts the normal electrical conduction pathway, creating favorable conditions for the occurrence of AF. Myocardial fibrosis also promotes the formation of ectopic pacemakers, which can trigger and maintain AF.

3.2. Electrophysiological changes and triggering of atrial fibrillation

Atrial fibrillation in DCM patients is associated with various electrophysiological changes. Myocardial fibrosis leads to weakened electrical coupling between atrial muscle cells, increasing electrical instability. In addition,
the non-uniformity of the action potential duration of atrial myocytes increases, which may lead to the formation of reentry circuits, which is another mechanism of AF occurrence. The triggering of atrial fibrillation is usually associated with rapid atrial rate, which may be caused by atrial ectopic pacing points such as pulmonary veins.

3.3. Imbalance of neurohumoral regulation and atrial fibrillation

The imbalance of neurohumoral regulation also plays an important role in the pathogenesis of AF. In DCM patients, the imbalance of sympathetic and parasympathetic nerve activity may lead to the occurrence and persistence of atrial fibrillation. The increase in sympathetic activity can enhance the automaticity and triggering activity of myocardial cells, while the increase in parasympathetic activity can shorten the duration of action potential in atrial muscle cells, both of which can promote the occurrence of AF. In addition, AF is also related to changes in the levels of certain hormones and cytokines in the plasma, such as adrenaline, norepinephrine, and inflammatory mediators, which may affect the occurrence of atrial fibrillation by altering the electrophysiological characteristics of myocardial cells.

4. Analysis of prediction models for AF in patients with DCM and HF

4.1. Explanation of the construction elements of the prediction model

The construction of prediction models is a complex process that involves comprehensive consideration of multiple factors. In patients with DCM and HF, models for predicting AF typically include the elements shown in Table 1.

<table>
<thead>
<tr>
<th>Essential factor</th>
<th>Illustration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical parameters</td>
<td>Age, gender, severity of HF, and history of heart disease, are crucial for assessing the risk of developing AF in patients.</td>
</tr>
<tr>
<td>Laboratory indicators</td>
<td>Electrolyte levels, myocardial enzyme markers, renal function indicators, etc. can reflect the patient’s metabolic status and cardiac load.</td>
</tr>
<tr>
<td>ECG parameters</td>
<td>P-wave duration, QRS complex, heart rate variability, and other indicators that reflect the electrophysiological state of the heart are of great value for predicting AF.</td>
</tr>
<tr>
<td>Imaging parameters</td>
<td>Parameters like cardiac cavity size, wall thickness, ejection fraction, etc., obtained through imaging examinations such as echocardiography, can intuitively reflect the structure and function of the heart.</td>
</tr>
<tr>
<td>Biomarkers</td>
<td>The levels of B-type natriuretic peptide (BNP), N-terminal pro-B-type natriuretic peptide (NT-proBNP), cardiac troponin, and other biomarkers are related to the degree of cardiac stress and injury, which can help predict the risk of AF.</td>
</tr>
</tbody>
</table>

4.1.1. Illustration

Clinical parameters are the most commonly used factors to predict AF, including age, gender, heart history, hypertension, diabetes, hyperlipidemia, left atrial hypertrophy, etc. Laboratory indicators can reflect the metabolic status and cardiac load of patients, including electrolyte levels, myocardial enzyme markers, and renal function indicators. Electrocardiogram parameters can reflect the electrophysiological state of the heart, including P-wave duration, QRS duration, heart rate variability, etc. Imaging parameters can intuitively reflect the structure and function of the heart, including chamber size, wall thickness, ejection fraction, etc. Biomarkers can reflect the degree of cardiac stress and injury, including BNP, NT-proBNP, cardiac troponin, etc.
4.1.2. Application
The AF prediction model can be used in several scenarios. The first application is in screening high-risk populations, which can assess the risk of developing AF in patients based on the predicted risks of the model, thereby focusing on monitoring and intervention for high-risk populations. The second application is to guide clinical treatment, which can adjust the patient’s treatment plan based on the predicted risks of the model to reduce the risk of AF occurrence. Lastly, the prediction model can also be used to evaluate the treatment effect, which can be evaluated based on the risk predicted by the model, thus guiding subsequent treatment.

4.2. Evaluation of existing prediction models
A review of existing literature shows that multiple prediction models have been proposed to assess the risk of AF in DCM patients. These models are based on different statistical methods and patient populations, and their predictive abilities vary.

4.2.1. Sensitivity, specificity, and accuracy analysis of the model
The effectiveness of prediction models is usually evaluated by their sensitivity (ability to correctly identify patients at AF risk), specificity (ability to correctly exclude patients without AF risk), and accuracy (overall prediction accuracy). An ideal prediction model should have high sensitivity and specificity, but in practical applications, it is often necessary to find a balance between the two.

4.2.2. Application and limitations of predictive models in clinical practice
Although prediction models are highly applicable in theory, there might be some limitations in clinical practice. For example, the accuracy of the model needs to be improved using a large amount of patient data, which might not be achievable in some cases. In addition, the model may need to be regularly updated to reflect the latest clinical practices and research findings. Lastly, individual factors of each patient including genetic factors, lifestyle, and other variables should also be considered when applying the prediction model.

5. Outlook and challenges
5.1. Discovery and application of new biomarkers
With the advancement of molecular biology and genomics, new biomarkers are constantly being discovered, which have the potential to improve the accuracy of predicting AF. For example, novel biomarkers such as inflammatory markers, microRNAs, and circulating DNA may play a role in future prediction models. The application of these biomarkers can not only improve the sensitivity and specificity of prediction, but also reveal new mechanisms of AF occurrence, providing new targets for treatment.

5.2. Role of advanced imaging technology in prediction models
Advanced imaging technologies such as cardiac magnetic resonance imaging (MRI), three-dimensional echocardiography, and computed tomography (CT) can provide more detailed information on cardiac structure and function. The development of these technologies, especially in the assessment of atrial structure and function, has provided new dimensions for the prediction of atrial fibrillation. Future prediction models may integrate data from these advanced imaging technologies to improve the accuracy of predictions.

5.3. Combination of personalized healthcare and precise prediction models
The rise of personalized healthcare emphasizes individual differences in treatment and prevention strategies.
The concept of precision medicine can be applied to the construction of prediction models, by considering individual genetic background, lifestyle, environmental factors, etc., to build more personalized atrial fibrillation risk assessment tools. This method may improve the value of prediction models in individual patients.

### 5.4. Importance of predictive models in clinical decision-making

The application of prediction models in clinical decision-making has been receiving increasing attention. An effective prediction model can help doctors identify high-risk patients and intervene early, potentially reducing the incidence of AF and related complications. In addition, prediction models can also be used to guide drug treatment and monitoring strategies, optimize resource allocation, and ultimately improve patients’ quality of life and prognosis.

### 6. Conclusion

This article reviews the current status and challenges in constructing predictive models for atrial fibrillation in patients with DCM and HF. Through the exploration of epidemiological data, pathophysiological mechanisms, and analysis of prediction models, we have gained a deeper understanding of the prediction of AF. Looking ahead, the application of new biomarkers, imaging technologies, and the development of personalized medicine will bring new opportunities for the prediction and management of AF. Despite the challenges, through interdisciplinary cooperation and technological advancements, we have the potential to improve the accuracy of prediction models and thus improve patient outcome.

### Disclosure statement

The authors declare no conflict of interest.

### References


---

**Publisher’s note**

Bio-Byword Scientific Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.